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Background: The relationship between circulating microRNA-223 and pathogenesis of acute ischemic stroke is
unknown. Here we investigated the roles and possible targets of circulating microRNA-223 in human ischemic
stroke within the first 72 hours.
Methods: Blood samples were collected from patients within 72 hours after cerebral ischemia (n = 79) and
compared with healthy control samples (n = 75). The level of possible downstream factors of microRNA-223 including
insulin-like growth factor-1, insulin-like growth factor-1 receptor and interleukin-6 was examined by ELISA assay. The
relationship between the microRNA-223 level and NIHSS scores, TOAST subtypes, and infarct volume was analyzed
respectively. In addition, twelve adult male CD-1 mice underwent middle cerebral artery occlusion using the suture
technique. Circulating blood and brain tissue in the ischemic ipsilateral hemisphere were collected at 24 hours after
middle cerebral artery occlusion. microRNA-223 was detected by real-time polymerase chain reactions.
Results: microRNA-223 levels in the circulating blood of acute ischemic stroke patients were greatly increased
compared to the control (p < 0.05). microRNA-223, which were negatively correlated with NIHSS scores (r = −0.531,
p < 0.01) and infarct volume (r = −0.265, p = 0.039), was significantly up-regulated in large artery and small artery
strokes. The plasma level of insulin-like growth factor-1 was positively associated with that of microRNA-223 (r = 0.205,
p = 0.022). Moreover, microRNA-223 in blood and brain were positively correlated (r = 0.834, p < 0.05), and they were
up-regulated significantly in mice that underwent middle cerebral artery occlusion (p < 0.05).
Conclusions: Our results suggest that microRNA-223 is associated with acute ischemic stroke and possibly plays a role
in stroke through up-regulating growth factor such as insulin-like growth factor-1 gene.
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microRNAs (miRNAs) are a class of 22 nucleotides, short
non-coding RNA molecules conserved in the genomes of
animals, plants and viruses [1]. miRNAs are important reg-
ulators of the development and function of the brain [2].
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city and oxidative damage [5], inflammatory reaction [6],
blood–brain barrier disruption and brain edema formation
[7,8]. miRNAs profiling is being utilized to identify sub-
types [9], diagnose diseases [10], instruct treatment plans
[11] and predict long term outcomes [12].
Great attention has been paid to miR-223 because it can
regulate cell cycle, tumor invasiveness, haematopoietic
differentiation and immune cell function [13]. miR-223 is
located in the X chromosome. Some known transcrip-
tional factors including NFI-A and C/EBPα regulate miR-
223 expression [14]. Studies demonstrated that miR-223 is
mainly expressed in bone marrow and plays an importanttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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regulates interleukin-6 (IL-6) and IL-1β expression in
TLR-activated macrophages [16]. During differentiation or
tumor progression, miR-223 suppresses cell proliferation by
targeting insulin-like growth factor-1 receptor (IGF1R) [17].
In hepatic ischemia/reperfusion injury, miR-223 is greatly
up-regulated and positively correlates with serum markers
of ischemic injury [18]. In the central nervous system miR-
223 is also highly present and is neuroprotective by targeting
GluR2 and NR2B subunits of the glutamate receptor [19].
However, the function of miR-223 associated with
acute ischemic brain injury (less than 72 hours) remains
unknown. The changes of miR-223 levels for stroke
diagnosis and their relationship with clinical confound
factors need to be explored. Here, we analyzed changes
of miR-223 levels in acute ischemic stroke patients and
animal ischemia model. We then assessed the relation-
ship between the alteration of circulating miR-223 levels
and the NIHSS scores, subtypes and infarct volume of
acute stroke patients. To explore the regulatory mechan-
ism of miR-223 in the ischemic pathological process, we
also studied the down-stream insulin-like growth factor-
1 (IGF-1), IGF1R and IL-6 changes in stroke patients.
Methods
Study subject
Subjects were enrolled in the study from July 2012 to
January 2013 and were approved by the Institutional
Review Board (IRB) of the Shanghai Jiao Tong University,
and gave informed consent. The control group included
subjects whose age and gender matched that of the stroke
patients. Demographic changes, associated laboratory
inspection, imaging information, which included blood
pressure, fasting blood glucose, cholesterol, triglyceride,
CT, MRI, MR angiography, carotid artery ultrasonog-
raphy and cardiac ultrasonography were also collected
to analyze. Whether subjects taking medicines including
antidiabets, hypotensor or platelet aggregation drugs
was also recorded. The exclusion criteria included
recurrent stroke, intracranial tumor, multiple trauma,
hematological system diseases, renal or liver failure,
acute infectious diseases and other diseases affecting
the hemogram. If the time from the onset of stroke
symptoms to blood sample collection was longer than
72 hours, the patient was excluded.
The severity of ischemic stroke was assessed by the
National Institutes of Health Stroke Scale (NIHSS) [20].
The patients were classified into the following groups:
large-artery atherosclerosis (LA, n = 37), cardioembolism
(CE, n = 5), small artery stroke (SA, n = 9) and undeter-
mined etiology (UN, n = 28) by the Trial of Org 10172
in Acute Stroke Treatment (TOAST) [21]. The infarct
volumes were calculated by ABC/2 method [22]. The risk
factors were defined as following: hypertension: bloodpressure above 140/90 mmHg; hyperlipidemia: total chol-
esterol level ≥ 0.7 mmol/L, triglyceride level ≥ 1.8 mmol/L
and HDL level < 1 mmol/L; Diabetes mellitus: fasting-
blood glucose level > 6.1 mmol/L or HbA1c ≥ 7% [23].
Middle cerebral artery occlusion in mice
Procedures for the use of laboratory animals were ap-
proved by the Shanghai Jiao Tong University Institutional
Animal Care and Use Committee, Shanghai, China. Adult
male CD-1 mice (n = 12) weighing 25–30 grams were
anesthetized with ketamine/xylazine (100 mg/10 mg/kg,
Sigma, San Louis, MO). Body temperature was controlled
and maintained at 37 ± 0.3°C using a heating pad (RWD
Life Science, Shenzhen, China) during the anesthesia
period. After isolation of left common carotid artery
(CCA), external and internal carotid artery (ECA, ICA), a
silicone-coated 6–0 suture (Covidien, Mansfield, MA) was
gently inserted from the ECA stump to the ICA, and
stopped at the opening of the MCA. The distance from
the bifurcation of ICA/ECA to MCA was 10 ± 0.5 mm
[24]. Successful occlusion was verified by a laser Doppler
flowmeter (Moor Instruments, Devon, UK). Mice with
surface cerebral blood flow that was more than 15% of
baseline were excluded from the experiment. Sham-
operated mice underwent the same surgery procedure
except inserting the suture into the ICA.
Preparation of blood and brain samples
A 4 ml blood sample from acute ischemic stroke pa-
tients was collected into tubes containing ethylenedi-
aminetetraacetic acid, and centrifuged at 1500 g for 10
minutes at room temperature. Then the erythrocytes
were dissociated with erythrocyte lysing solution and
discarded, the remaining leucocytes were held for total
RNA extraction.
The brains of mice were rapidly removed and cut into
four coronal sections 2 mm apart. The second slice was
divided into ischemic ipsilateral and contralateral hemi-
spheres. The ischemic ipsilateral brain tissue and blood
collected for total RNA extraction using TRIzol and
TRIzol LS reagent respectively (Invitrogen, Carlsbad).
Reverse transcription and Real-time PCR
RNA concentration and purity were detected by the
NanoDrop1000 spectrophotometer (Thermo, Wilmington,
DE). The samples of absorbance at 260–280 nm between
1.8 and 2.0 were adopted. First strand cDNA was synthe-
sized from 10 ng RNA using universal cDNA synthesis kit
(EXIQON, Vedbaek, Denmark). The amplification was
performed by a fast real-time PCR system (7900 HT,
ABI, Foster City, CA) using a SYBR Green master mix
(EXQION) following the cycling conditions: 95°C for
10 minutes followed by 40 cycles of 95°C for 10 seconds,
and 60°C for 1 minute. miR-223 relative expression was
Table 1 Clinical characteristics of the healthy control and acute ischemic stroke patients
Control Acute ischemic stroke p
1d 2d 3d Total
Total (N) 75 15 22 42 79 1.00
Race (Asian,%) 100% 100% 100% 100% 100% 1.00
Ethnicity (Han,%) 100% 100% 100% 100% 100% 1.00
Age (years, Mean ± SD) 62.5 ± 6.3 70.0 ± 13.46 66.50 ± 9.55 63.0 ± 9.09 65.1 ± 10.0 0.053
Sex (male/female, N) 50/25 11/4 18/4 29/13 58/21 0.383
Hypertension (N,%) 27 (36%) 12 (80%) 17 (77.3%) 32 (76.2%) 61 (77.2%) <0.05
Diabetes (N,%) 4 (5.3%) 4 (26.7%) 8 (36.4%) 19 (45.2%) 31 (39.2%) <0.05
Hyperlipidemia (N,%) 28 (37.3%) 10 (66.7%) 14 (63.6%) 24 (57.1%) 48 (60.8%) <0.05
Cardiopathy (N,%) 2 (2.7%) 4 (26.7%) 1 (4.5%) 2 (4.8%) 7 (8.9%) 0.10
NIHSS (Mean, Min, Max) NA 4.73 (1, 11) 5.05 (0, 20) 3.10 (0, 10) 3.95 (0, 20) NA
TS
LA (N,%) NA 6 (40%) 14 (63.6%) 17 (40.5%) 37 NA
CE (N,%) NA 3 (20%) 0 2 (4.8%) 5 NA
SA (N,%) NA 1 (6.7%) 1 (4.5%) 7 (16.7%) 9 NA
UN (N,%) NA 5 (33.3%) 7 (31.8%) 16 (38.1%) 28 NA
TS = TOAST subtype; NA, data not available.
Figure 1 Blood miR-223 levels were significantly increased in
acute ischemic stroke. Box plots showed the expression of blood
miR-223 in patients and control. The Y axis indicated miR-223 expression
levels by log2 change. *, p< 0.05, stroke patients vs. control. Data are
median (25% percentile, 75% percentile), n = 79 in stroke group, n = 75
in control group.
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triplicate and was calculated by the 2-Δct method.
Enzyme-linked Immunosorbent Assay (ELISA)
The levels of human plasma IGF-1, IGF1R and IL-6 were
measured by ELISA kits (Westang Bio-Tech, Shanghai,
China) according to the manufacturer’s protocols. The
intra- and inter-assay CV are less 10%.
Statistical analysis
The results were expressed as percentages for categorical
variables and as mean ± SD or median and range (25th
and 75th percentiles) for the continuous variables de-
pending on whether their distribution was normal or
not. The Kolmogorov-Smirnov test was used for testing
the normality of the distribution. Proportions were com-
pared using the chi-square test, while the continuous
variables between groups were compared with the Stu-
dent’s t or the Mann–Whitney tests. Spearman’s analysis
was used for bivariate correlations depending on their
non-normal distribution. ANOVA should be used for
comparison among several quantitative variables. The
influence of miR-223 levels on a categorical variable was
assessed by logistic regression analysis using forward
stepwise selection procedures after adjusting for those
variables with a proven biological relevance for stoke
mobidity to avoid the possibility of finding some spuri-
ous associations. Results were expressed as adjusted
odds ratios (OR) with the corresponding 95% confidence
intervals (95% CI). Significance was set at a probability
p < 0.05.Results
Baseline clinical characteristics
The characteristics of ischemic stroke patients and
controls enrolled in this study are shown in Table 1.
On admission, the ages of the stroke patients were
65.1 ± 10.0 years and the ages of the control group were
62.5 ± 6.3 years (p = 0.053). The number of males in
both groups was about double that of females (male/
female = 58/21 in ischemic group and male/female = 50/25
in control group, p = 0.383). To eliminate unmatched fac-
tor impaction (hypertension, diabetes and hyperlipidemia)
Figure 2 The time course of miR-223 expression and the correlation analysis between miR-223 and clinical information. A. miR-223 was
highly expressed in 1 day and 3 days stroke patients. Box plots exhibited the time course of miR-223 expression in stroke patients. *, p < 0.05,
1 day vs. control; **, p < 0.01, 3 days vs. control. n = 75 in control group, n = 15 in 1 day group, n = 22 in 2 days group, n = 42 in 3 days group.
B. miR-223 was significantly up-regulated in patients with LA and SA strokes. Box plots exhibited the miR-223 expression level among different
subtypes. *, p < 0.05, LA vs. control; **, p < 0.01, SA vs. control. n = 75 in control, n = 37 in LA, n = 5 in CE, n = 9 in SA, n = 28 in UN. Data are median
(25% percentile, 75% percentile). The Y axis showed the miR-223 expression levels by log2 change. C. The scatterplot showed miR-223 levels were
negatively associated with NIHSS scores. r = −0.531, p < 0.01. D. The scatterplot showed miR-223 levels have a negative correlation with infarct volume
of stroke patients. r = −0.265, p = 0.039.
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tic regression was performed. The results of logistic re-
gression suggested that the level of blood miR-223 was a
stroke risk factor (p = 0.011, adjusted odd ratio = 1.002,
95% CI: 1.000-1.004).
The expression levels and the time course of blood
miR-223 in acute ischemic stroke patients
miR-223 levels in the blood of acute ischemic patients
were elevated compared with the control subjects [Figure 1,
stroke vs. control, 141.57 (12.45, 715.12) vs. 40.64 (3.13,
162.80)]. miR-223 expression was up-regulated in the
1 day and 3 days groups following stroke occurrenceFigure 3 Blood and brain miR-223 levels were elevated and they hav
of miR-223 in brain tissue and blood of MCAO mice at 1 day. *, p < 0.05; **, p
scatter plot demonstrated the positive correlation between blood miR-223 ancompared to the control [Figure 2A, 1 day vs. control,
146.92 (23.72, 700.05) vs. 40.64 (3.13, 162.80), p < 0.05;
3 days vs. control, 224.76 (17.41, 1700.63) vs. 40.64 (3.13,
162.80), p < 0.01]. In addition, the difference between
patient with/without antidiabets, hypotensor or platelet
aggregation drugs was analyzed respectively. We did
not find the significant difference of the expression
levels of miR-223 (data not shown here).
The relationship between miR-223 and TOAST subtypes,
NIHSS scores and infarct volume
miR-223 expression levels of LA or SA stroke patients were
significantly increased [Figure 2B, LA vs. control, 143.46e a positive correlation in mice. A. Bar graphs showed the expression
< 0.01, MCAO vs. sham. Data are mean ± SD, n = 6 in each group. B. The
d brain miR-223 at 1 day after ischemia. r = 0.834, p < 0.05, n = 6.
Table 2 The expression of IGF-1, IGF1R and IL-6 in ischemic stroke patients and control
Control N = 75 1d N = 15 2d N = 22 3d N = 42 Total N = 79 P
IGF-1 (ng/ml) 73.30 (44.22, 114.54) 134.21 (69.34, 251.37) 76.55 (56.24, 142.51) 132.36 (76.58, 188.79) 111.44 (69.54, 184.22) 0.001
IGF1R (ng/ml) 10.93 (9.87, 12.36) 12.49 (11.33, 17.03) 12.45 (9.34, 15.09) 12.20 (10.07, 17.91) 12.45 (10.31, 16.75) 0.004
IL-6 (ng/ml) 28.56 (19.87, 52.85) 29.52 (22.36, 40.90) 21.57 (19.04, 30.49) 34.73 (21.61, 57.80) 29.04 (20.13, 54.36) 0.909
Data are median (25% quartile, 75% quartile).
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control, 312.35 (73.16, 1466.71) vs. 40.64 (3.13, 162.80),
p < 0.01]. miR-223 expression levels were negatively associ-
ated with NIHSS scores (Figure 2C, r = −0.531, p < 0.01)
and infarct volume (Figure 2D, r = −0.265, p = 0.039).
Brain and blood miR-223 in ischemic mice
miR-223 was significantly up-regulated in both brain and
blood samples compared to that of the sham in MCAO
mice (Figure 3A, brain, MCAO vs. sham, 0.06 ± 0.01 vs.
0.02 ± 0.007, p < 0.05; blood, MCAO vs. sham, 5.95 ± 0.92
vs. 3.47 ± 0.43, p < 0.01). A positive correlation between
the blood miR-223 and the brain miR-223 levels was
analyzed by Spearman’s correlation analysis (Figure 3B,
r = 0.834, p < 0.05).
The correlation between miR-223 and potential target
genes
The levels of plasma IGF-1 and IGF1R were greatly in-
creased in the stroke patients group compared to the
control group (Table 2). IGF-1 levels changed with miR-
223 levels in the 1 day, 2 days and 3 days groups after
ischemia (Figure 4A) and miR-223 expression was posi-
tively associated with IGF-1 levels (Figure 4C, r = 0.205,
p = 0.022). There was no significant correlation betweenFigure 4 The relationship between miR-223 and IGF1R, IGF-1 and IL-6
within 72 hours. Data are median, n = 75 in control, n = 15 in 1 day group, n =
miR-223 was not associated with IGF1R after ischemia. r = −0.023, p = 0.795. C
r = 0.205, p = 0.022. D. The scatterplot showed miR-223 was not associated wimiR-223 expression and IGF1R (Figure 4B, r = −0.023,
p = 0.795) and IL-6 (Figure 4D, r = −0.058, p = 0.522).
Discussion
In this study, we demonstrated that miR-223 was hyper-
expressed in the circulating blood of acute ischemic
stroke patients. The severity of stroke and the infarct
volume of stroke patients were negatively associated
with miR-223 expression. miR-223 levels were greatly in-
creased in patients with LA and SA stroke. The plasma
level of IGF-1 has a positive correlation to miR-223
level. Brain miR-223 and blood miR-223 level were sig-
nificantly elevated and have a positive correlation in
MCAO mice.
Previous animals’ experiments demonstrated that miR-
223 level was significantly elevated at 24 and 72 hour re-
perfusion in rat transient MCAO [25] and at 3 and
24 hours in ischemic preconditioning [26]. Another
study of miR-223 expression proved that miR-223 was
greatly increased in the blood of young stroke patients
aged 18–49 years [23]. In our study, we found the simi-
lar changes of miR-223 expression in the blood of acute
ischemic stroke patients and that the brain miR-223
level positively correlated with blood miR-223 level in
ischemic mice. The result suggested that miR-223 is. A. Line chart exhibited the changes of miR-223, IGF-1, IGF1R and IL-6
22 in 2 days group, n = 42 in 3 days group. B. The scatterplot showed
. The scatterplot demonstrated miR-223 was positively correlated to IGF-1.
th IL-6 after ischemia. r = −0.058, p = 0.522.
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implied that blood miR-223 represents the changes of
miR-223 in brain response to ischemic stroke.
Blood samples were obtained within 72 hours of stroke
onset and molecular studies have shown considerable vari-
ability in the acute period (Figure 2A). Maybe this is a rela-
tive broad time range for the expression of miR-223.
Besides, to obtain a temporal expression profile of miR-223
in patients, it is perfect for the extraction of basal samples
from the same patients at 24, 48 and 72 hours. This prob-
lem could be solved in further studies. In general, ischemic
stroke classified as LA, CE, SA and Undetermined accord-
ing TOAST subtype classification. We classified inpatients
as LA, CE, SA and UN in our study group and found that
LA and UN are the main subtypes. This may be different
from other studies, we consider it may be caused by
the ethnic group. In the study, miR-223 expression of
the stroke patients with LA or SA showed similar up-
regulation. However, miR-223 showed opposite expression
patterns in LA or SA stroke within 6–18 months [23]. The
difference might be caused by the different blood sample
collection times. NIHSS scores indicate the severity of
ischemic stroke. The mean NIHSS in our studies is relative
low, suggesting miR-223 is sensitive for mild stroke.
Whether miR-223 associated with the severe stroke needs
to be further studied. NIHSS scores had a negative correl-
ation with miR-223 expression in our study, implying the
potential neuroprotective role of miR-223 in stroke.
The therapeutic potential of IGF-1 for ischemic brain
injury had been proved [27,28]. In the study, IGF-1 level
changed with miR-223 levels in the 1 day, 2 days and
3 days groups after ischemia, suggesting the modulation
of miR-223 on IGF-1 expression. In vitro studies have
demonstrated that miR-223 could specifically regulate
IGF1R expression [17]. However, we did not find a simi-
lar correlation between miR-223 and IGF1R in the blood
of patients with acute ischemia. The reason for the
difference between in vitro and in vivo studies was
unclear. Increasing evidences suggest miR-223 plays a
vital role in modulating inflammatory reactions [15].
IL-6 could induce the decrease of miR-223 expression
after lipopolysaccharide stimulation in macrophages
[16]. But we did not find a correlation between miR-
223 and IL-6 levels in vivo. It was plausible to assume
that miR-223 takes part in the early inflammatory reac-
tion after stoke through other pathways.
Stroke is a neurological emergency where time has an
extraordinary value for clinical or therapeutic decisions.
As a result, a useful biomarker for stroke should be
determined in a very short period of time. To develop a
novel technique quickly detect the changes of miR-223
will greatly help to the diagnosis of stroke. Moreover,
RNA stabilizing agent is better than EDTA tube, which
is modified in future study.Conclusions
The study reported circulating miR-223 based markers
for acute ischemic stroke occurrence, subtypes and infarct
volume. Our findings suggested IGF-1 might be a new tar-
get of miR-223. Further studies with larger sample sizes
are needed to assess the clinical application of miR-223
signatures. We believe that miR-223 has great potential as
a novel therapeutic target for ischemic stroke.
Abbreviations
ECA: External carotid artery; IGF-1: Insulin-like growth factor-1; IGF1R:
Insulin-like growth factor-1 receptor; IL-1β: interlukin-1β; IL-6: Interlukin-6;
ICA: Internal carotid artery; MCAO: middle cerebral artery occlusion;
miR-223: microRNA-223; NIHSS: National Institutes of Health Stroke Scale;
TOAST: Trial of Org 10172 in acute stroke treatment criteria.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YW and YZ were involved in research design, clinical samples and materials
collection and experimental performance, analyzing the data as well as
drafting the manuscript. JH did animal surgery. XC and XG gave technical
assistant. YW discussed the results and edited the part of manuscript. LZ and
GYY are the corresponding authors, they took the whole consideration for
this study, including research design, data analysis, results discussion, and
manuscript preparation. All authors read and approved the final manuscript.
Acknowledgements
The authors also thank Bingshun Wang and Xiaojin Wang who provide the
statistic analysis services. This study is supported by Science and Technology
and Technology Commission of Shanghai Municipality #13140903500 (GYY),
NSFC Project #81070939 (GYY) and #81200943 (LZ), the Shanghai medical
association (SHNR-003, LZ), Shanghai healthy bureau (20124217, LZ).
Author details
1Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University,
School of Medicine, 197 Ruijin Er Road, 200025 Shanghai, China.
2Neuroscience and Neuroengineering Research Center, Med-X Research
Institute and School of Biomedical Engineering, Shanghai Jiao Tong
University, 1954 Hua Shan Road, 200030 Shanghai, China.
Received: 13 January 2014 Accepted: 4 April 2014
Published: 8 April 2014
References
1. Kim VN: MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev
Mol Cell Biol 2005, 6:376–385.
2. Kapsimali M, Kloosterman WP, de Bruijn E, Rosa F, Plasterk RH, Wilson SW:
MicroRNAs show a wide diversity of expression profiles in the developing
and mature central nervous system. Genome Biol 2007, 8:R173.
3. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A,
Weger S, Oberhollenzer F, Bonora E, Shah A, Willeit J, Mayr M: Plasma
microRNA profiling reveals loss of endothelial miR-126 and other
microRNAs in type 2 diabetes. Circ Res 2010, 107:810–817.
4. Yin KJ, Deng Z, Huang H, Hamblin M, Xie C, Zhang J, Chen YE: miR-497
regulates neuronal death in mouse brain after transient focal cerebral
ischemia. Neurobiol Dis 2010, 38:17–26.
5. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada
T, Dolan BM, Sharp PA, Sheng M: Regulation of synaptic structure and
function by FMRP-associated microRNAs miR-125b and miR-132. Neuron
2010, 65:373–384.
6. Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ: MicroRNA-126
regulates endothelial expression of vascular cell adhesion molecule 1.
Proc Natl Acad Sci U S A 2008, 105:1516–1521.
7. Sepramaniam S, Armugam A, Lim KY, Karolina DS, Swaminathan P, Tan JR,
Jeyaseelan K: MicroRNA 320a functions as a novel endogenous
modulator of aquaporins 1 and 4 as well as a potential therapeutic
target in cerebral ischemia. J Biol Chem 2010, 285:29223–29230.
Wang et al. BMC Neurology 2014, 14:77 Page 7 of 7
http://www.biomedcentral.com/1471-2377/14/778. Sepramaniam S, Ying LK, Armugam A, Wintour EM, Jeyaseelan K: MicroRNA-
130a represses transcriptional activity of aquaporin 4 M1 promoter. J Biol
Chem 2012, 287:12006–12015.
9. Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F: microRNAs as
peripheral blood biomarkers of cardiovascular disease. Vascul Pharmacol
2011, 55:111–118.
10. Cortez MA, Calin GA: MicroRNA identification in plasma and serum: a
new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009,
9:703–711.
11. Bai H, Wei J, Deng C, Yang X, Wang C, Xu R: MicroRNA-21 regulates the
sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemo-
therapy regimen. Int J Hematol 2013, 97:223–231.
12. Schulte JH, Schowe B, Mestdagh P, Kaderali L, Kalaghatgi P, Schlierf S,
Vermeulen J, Brockmeyer B, Pajtler K, Thor T, de Preter K, Speleman F, Morik
K, Eggert A, Vandesompele J, Schramm A: Accurate prediction of
neuroblastoma outcome based on miRNA expression profiles. Int J
Cancer 2010, 127:2374–2385.
13. Haneklaus M, Gerlic M, O’Neill LA, Masters SL: miR-223: infection,
inflammation and cancer. J Intern Med 2013, 274:215–226.
14. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, Bozzoni I: A
minicircuitry comprised of microRNA-223 and transcription factors NFI-A
and C/EBPalpha regulates human granulopoiesis. Cell 2005, 123:819–831.
15. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O,
Brummelkamp TR, Fleming MD, Camargo FD: Regulation of progenitor cell
proliferation and granulocyte function by microRNA-223. Nature 2008,
451:1125–1129.
16. Chen Q, Wang H, Liu Y, Song Y, Lai L, Han Q, Cao X, Wang Q: Inducible
microRNA-223 down-regulation promotes TLR-triggered IL-6 and IL-1beta
production in macrophages by targeting STAT3. PLoS One 2012, 7:e42971.
17. Jia CY, Li HH, Zhu XC, Dong YW, Fu D, Zhao QL, Wu W, Wu XZ: MiR-223
suppresses cell proliferation by targeting IGF-1R. PLoS One 2011, 6:e27008.
18. Yu CH, Xu CF, Li YM: Association of MicroRNA-223 expression with
hepatic ischemia/reperfusion injury in mice. Dig Dis Sci 2009, 54:2362–2366.
19. Harraz MM, Eacker SM, Wang X, Dawson TM, Dawson VL: MicroRNA-223 is
neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci U S A
2012, 109:18962–18967.
20. Special report from the National Institute of Neurological Disorders and
Stroke: Classification of cerebrovascular diseases III. Stroke 1990, 21:637–676.
21. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, 3rd
Marsh EE: Classification of subtype of acute ischemic stroke Definitions
for use in a multicenter clinical trial TOAST Trial of Org 10172 in Acute
Stroke Treatment. Stroke 1993, 24:35–41.
22. Sims JR, Gharai LR, Schaefer PW, Vangel M, Rosenthal ES, Lev MH,
Schwamm LH: ABC/2 for rapid clinical estimate of infarct, perfusion, and
mismatch volumes. Neurology 2009, 72:2104–2110.
23. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW,
Jeyaseelan K: Expression profile of MicroRNAs in young stroke patients.
PLoS One 2009, 4:e7689.
24. Huang J, Li Y, Tang Y, Tang G, Yang GY, Wang Y: CXCR4 antagonist
AMD3100 protects blood–brain barrier integrity and reduces inflammatory
response after focal ischemia in mice. Stroke 2013, 44:190–197.
25. Dharap A, Bowen K, Place R, Li LC, Vemuganti R: Transient focal ischemia
induces extensive temporal changes in rat cerebral microRNAome. J Cereb
Blood Flow Metab 2009, 29:675–687.
26. Lee ST, Chu K, Jung KH, Yoon HJ, Jeon D, Kang KM, Park KH, Bae EK, Kim M,
Lee SK, Roh JK: MicroRNAs induced during ischemic preconditioning.
Stroke 2010, 41:1646–1651.
27. Zhu W, Fan Y, Hao Q, Shen F, Hashimoto T, Yang GY, Gasmi M, Bartus RT,
Young WL, Chen Y: Postischemic IGF-1 gene transfer promotes neurovas-
cular regeneration after experimental stroke. J Cereb Blood Flow Metab
2009, 29:1528–1537.
28. Zhu W, Fan Y, Frenzel T, Gasmi M, Bartus RT, Young WL, Yang GY, Chen Y:
Insulin growth factor-1 gene transfer enhances neurovascular remodeling
and improves long-term stroke outcome in mice. Stroke 2008, 39:1254–1261.
doi:10.1186/1471-2377-14-77
Cite this article as: Wang et al.: Increase of circulating miR-223 and insulin-
like growth factor-1 is associated with the pathogenesis of acute ischemic
stroke in patients. BMC Neurology 2014 14:77.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
